Published in PLoS One on July 01, 2016
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A (2007) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell (2014) 2.57
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol (2004) 2.16
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nat Protoc (2007) 1.82
Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol (2002) 1.68
Mechanisms of fenretinide-induced apoptosis. Apoptosis (2006) 1.64
Retinoids in cancer therapy. J Clin Oncol (1992) 1.59
Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res (2008) 1.30
Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer (2001) 1.23
Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene (2011) 1.22
Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol (2006) 1.18
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.16
Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev (2008) 1.14
CD133: to be or not to be, is this the real question? Am J Transl Res (2013) 1.12
The 'chemoinvasion' assay, 25 years and still going strong: the use of reconstituted basement membranes to study cell invasion and angiogenesis. Curr Opin Cell Biol (2010) 1.11
Determination of somatic and cancer stem cell self-renewing symmetric division rate using sphere assays. PLoS One (2011) 1.11
Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis (2009) 1.09
Therapeutic strategies targeting cancer stem cells. Cancer Sci (2015) 1.07
N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene (2006) 1.06
Recent developments and current concepts in medulloblastoma. Cancer Treat Rev (2013) 1.05
Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03
Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) (2009) 1.01
N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell invasion through suppressing NF-KB activation and inhibiting matrix metalloproteinase-9 expression. J Cell Biochem (2012) 0.99
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol (2004) 0.98
The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res (2005) 0.98
Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res (2000) 0.97
Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property? Cell Cycle (2013) 0.97
Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer (2011) 0.97
Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells in vitro. Anticancer Drugs (2013) 0.96
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol (2016) 0.95
Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann N Y Acad Sci (2004) 0.94
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
Strategies to Prevent "Bad Luck" in Cancer. J Natl Cancer Inst (2015) 0.92
Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci U S A (2013) 0.92
Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res (1999) 0.91
Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate (2010) 0.90
Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit Rev Oncol Hematol (2010) 0.90
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev (2013) 0.89
Retinoid signaling in control of progenitor cell differentiation during mouse development. Semin Cell Dev Biol (2013) 0.89
Medulloblastoma stem cells: where development and cancer cross pathways. Pediatr Res (2012) 0.89
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs (2009) 0.88
Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? J Biomed Biotechnol (2012) 0.88
Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice. Curr Pediatr Rev (2015) 0.87
The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability. Mol Cancer (2010) 0.87
Medullospheres from DAOY, UW228 and ONS-76 cells: increased stem cell population and proteomic modifications. PLoS One (2013) 0.87
Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther (2011) 0.86
Seeing through the dark: New insights into the immune regulatory functions of vitamin A. Eur J Immunol (2015) 0.85
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis (2005) 0.85
Pediatric medulloblastoma - update on molecular classification driving targeted therapies. Front Oncol (2014) 0.85
Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther (2007) 0.84
Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis. Free Radic Biol Med (2010) 0.82
The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment. Aging Cell (2013) 0.82
Cancer stem cells and the tumor microenvironment: soloists or choral singers. Curr Pharm Biotechnol (2011) 0.82
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemother Pharmacol (2010) 0.82
Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling. Antioxid Redox Signal (2013) 0.82
Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett (2006) 0.82
Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol (2015) 0.82
N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int J Cancer (1999) 0.81
Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res (2009) 0.81
Ovarian and breast cancer spheres are similar in transcriptomic features and sensitive to fenretinide. Biomed Res Int (2013) 0.81
In vitro stemness characterization of radio-resistant clones isolated from a medulloblastoma cell line ONS-76. J Radiat Res (2012) 0.80
Spheres without influence: dissociating in vitro self-renewal from tumorigenic potential in glioma. Cancer Cell (2012) 0.80
Brain metastasis-initiating cells: survival of the fittest. Int J Mol Sci (2014) 0.80
Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol (1999) 0.80
Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol (2008) 0.79
Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J Control Release (2013) 0.78
The proteomics of cancer stem cells: potential clinical applications for innovative research in oncology. Proteomics Clin Appl (2011) 0.77
Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells. Cancer Chemother Pharmacol (2010) 0.77
Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model. Oncotarget (2014) 0.76
[Analysis of selected undesirable effects of cytostatic drugs in treatment of the central nervous system tumours in children. Preliminary report]. Med Wieku Rozwoj (2008) 0.76
Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. Biomed Pharmacother (2014) 0.76
Targeted Therapy Makes Inroads in Medulloblastoma. J Natl Cancer Inst (2015) 0.76
Fenretinide: a novel treatment for endometrial cancer. PLoS One (2014) 0.76
Shedding light on adult medulloblastoma: current management and opportunities for advances. Am Soc Clin Oncol Educ Book (2014) 0.75